Natural Substance Derivative DHNB is A Novel Xanthine Oxidase Inhibitor

天然物质衍生物DHNB是一种新型黄嘌呤氧化酶抑制剂

基本信息

  • 批准号:
    8443691
  • 负责人:
  • 金额:
    $ 16.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-04-01 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Gout is caused by hyperuricemia, which is an abnormally high level of uric acid in the blood. Gout prevalence is about 3.9% for general population. In addition, comorbidities of gout and hyperuricemia are increasing, including metabolic syndrome, hypertension hyperlipidemia, chronic kidney disease, diabetes, and coronary artery disease. The key enzyme involved in purine catabolism is xanthine oxidase (XO), which is the major target for therapeutic treatment of hyperuricemia and gout. Current drugs targeting XO include Allopurinol and Febuxostat, which have many side effects. There is a pressing clinical need for new, safe and effective drugs for this purpose. Recently, we have discovered, for the first time, that 3,4-dihydroxy-5- nitrobenzaldehyde (DHNB), a derivative of the natural compound protocatechuic aldehyde (3,4- dihydroxybenzaldehyde), is a potent XO inhibitor in vitro and in vivo. In addition, we have shown that DHNB has a strong scavenging effect on peroxynitrite and HOCl, while Allopurinol lacks this effect. This proposal is designed to study the efficacy, pharmacokinetics and toxicity of DHNB for hyperuricemia in mice. Specifically, we will determine the therapeutic efficacy of DHNB for XO inhibition and study the pharmacokinetics of DHNB in mice; determine the potential toxicity of DHNB in mice; and determine whether DHNB interacts with the FAD cofactor and/or molybdenum cofactor of XO. The major innovation of the project is the discovery and development of a new, potent, and safe XO inhibitor which can be used clinically to treat and prevent gout and hyperuricemia-associated diseases.
描述(由申请人提供):痛风是由高尿酸血症引起的,高尿酸血症是血液中尿酸水平异常高。一般人群中痛风患病率约为3.9%。此外,痛风和高尿酸血症的合并症也在增加,包括代谢综合征、高血压、高脂血症、慢性肾病、糖尿病和冠状动脉疾病。黄嘌呤氧化酶(XO)是参与嘌呤代谢的关键酶,是高尿酸血症和痛风治疗的主要靶点。目前针对XO的药物包括别嘌呤醇和非布司他,它们有许多副作用。临床上迫切需要用于此目的的新的、安全的和有效的药物。最近,我们首次发现,3,4-二羟基-5-硝基苯甲醛(DHNB),天然化合物原儿茶醛(3,4-二羟基苯甲醛)的衍生物,是一种有效的XO抑制剂在体外和体内。此外,我们已经表明,DHNB具有很强的清除过氧亚硝酸根和HOCl的作用,而别嘌呤醇缺乏这种效果。这项建议旨在 研究DHNB对小鼠高尿酸血症的疗效、药代动力学和毒性。具体而言,我们将确定DHNB对XO抑制的治疗效果,并研究DHNB在小鼠中的药代动力学;确定DHNB在小鼠中的潜在毒性;并确定DHNB是否与XO的FAD辅因子和/或钼辅因子相互作用。该项目的主要创新是发现和开发一种新的,有效的,安全的XO抑制剂,可用于临床治疗和预防痛风和高尿酸血症相关疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Changyi Chen其他文献

Changyi Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Changyi Chen', 18)}}的其他基金

Molecular Surgeon Symposium on Genetics and Genomics of Pancreatic Cancer
分子外科医生胰腺癌遗传学和基因组学研讨会
  • 批准号:
    7408620
  • 财政年份:
    2008
  • 资助金额:
    $ 16.63万
  • 项目类别:
Molecular Surgeon Research Training on Vascular Disease
分子外科医生血管疾病研究培训
  • 批准号:
    7343457
  • 财政年份:
    2008
  • 资助金额:
    $ 16.63万
  • 项目类别:
Molecular Surgeon Research Training on Vascular Disease
分子外科医生血管疾病研究培训
  • 批准号:
    8316269
  • 财政年份:
    2008
  • 资助金额:
    $ 16.63万
  • 项目类别:
Molecular Surgeon Research Training on Vascular Disease
分子外科医生血管疾病研究培训
  • 批准号:
    7902294
  • 财政年份:
    2008
  • 资助金额:
    $ 16.63万
  • 项目类别:
Molecular Surgeon Research Training on Vascular Disease
分子外科医生血管疾病研究培训
  • 批准号:
    7676707
  • 财政年份:
    2008
  • 资助金额:
    $ 16.63万
  • 项目类别:
Molecular Surgeon Research Training on Vascular Disease
分子外科医生血管疾病研究培训
  • 批准号:
    8132897
  • 财政年份:
    2008
  • 资助金额:
    $ 16.63万
  • 项目类别:
Molecular Surgeon Symposium on Vascular Injury, Repair
分子外科医生血管损伤、修复研讨会
  • 批准号:
    7057158
  • 财政年份:
    2005
  • 资助金额:
    $ 16.63万
  • 项目类别:
Effects of HAART drugs on endothelial dysfunction of pu*
HAART药物对pu*内皮功能障碍的影响
  • 批准号:
    7123488
  • 财政年份:
    2005
  • 资助金额:
    $ 16.63万
  • 项目类别:
Effects of HAART drugs on endothelial dysfunction of pu*
HAART药物对pu*内皮功能障碍的影响
  • 批准号:
    7250204
  • 财政年份:
    2005
  • 资助金额:
    $ 16.63万
  • 项目类别:
Effects of HAART drugs on endothelial dysfunction of pu*
HAART药物对pu*内皮功能障碍的影响
  • 批准号:
    7037236
  • 财政年份:
    2005
  • 资助金额:
    $ 16.63万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 16.63万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 16.63万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 16.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 16.63万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 16.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 16.63万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 16.63万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 16.63万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 16.63万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 16.63万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了